BIOMARIN PHARMACEUTICAL INC (BMRN)

64.67USD -0.95% (-0.62)

Over 1M: +7.7%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

60 65 70
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 776.1M Q3 '25 — Operating Cash Flow: 368.7M Q3 '25 — Free Cash Flow: 340.2M Q3 '25 — Net Income: -30.7M Q4 '25 — Revenue: 874.6M Q4 '25 — Operating Cash Flow: 99.6M Q4 '25 — Free Cash Flow: 58.9M Q4 '25 — Net Income: -46.6M Q1 '26 — Revenue: 766.2M Q1 '26 — Operating Cash Flow: 220.7M Q1 '26 — Free Cash Flow: 199.7M Q1 '26 — Net Income: 105.5M Q2 '26 — Revenue: 989.7M Q2 '26 — Operating Cash Flow: 168.1M Q2 '26 — Free Cash Flow: 139.3M Q2 '26 — Net Income: 44.8M 0 250M 500M 750M 1B
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 62 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

3.5
OE margin 15.3%
ROIC 1.1%
Accruals -6.7%
Gross margin 76.1%
OCF / EBIT 5.7×
FCF margin 21.7%
OCF margin 25.2%
ROA 0.62%
ROCE 1.5%
ROE 1.2%

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

3.4
EV/OE 31.5×
EV/EBIT 110.5×
P/B 2.0×
FCF yield 5.9%
P/C 14.3×
EV/Sales 4.8×
P/E 171.5×
Div. yield —
EV/GP —
Fwd P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

5.1
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

3.6
ND/EBITDA -0.24
Payout 0.0%
Debt / Eq 0.77×
Net debt / Eq 0.63×
Quick ratio 1.3×
Cash / Debt 0.18×
Debt payback 5.4 yr
F-score 4.5 pts
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

2.4
Sales CAGR 4Y +14.9%
Sales/sh Y/Y +10.8%
Shares change +0.35%
Sales Q/Q +19.9%
EBIT CAGR -2.1%
EBIT Y/Y -80.8%
EPS Y/Y -88.9%
Div. growth —
EPS CAGR 4Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.